AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine coadministration with antacid
Number of subjects: 8
Study 31633760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric-specific tumescent vasopressor solution and vasopressor-soaked topical compresses
Number of subjects: 61
Study 31633760 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hemostasis management)
Number of subjects: 61
Study 29916084 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 17
Study 29916084 — intervention group
Group type: COMPARATOR
Intervention: CGRP
Number of subjects: 17
Study 29916084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29916084 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil and CGRP
Number of subjects: 17
Study 26923086 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected mealtimes implementation
Number of subjects: 0
Study 24768940 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated telemedicine counseling (ITM) delivered via 2-way webcams in physician's office
Number of subjects: 566
Study 24768940 — intervention group
Group type: COMPARATOR
Intervention: Quitline counseling delivered by telephone (Phone)
Number of subjects: 566
Study 22184058 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 1366
Study 22184058 — intervention group
Group type: COMPARATOR
Intervention: No maternal smoking during pregnancy
Number of subjects: 1366
Study 22184058 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cotinine >1.3 ng ml(‐1)
Number of subjects: 1366
Study 20698896 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAHPS graphs
Number of subjects: 309
Study 20698896 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative's narrative e-mail
Number of subjects: 309
Study 20698896 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent information between HCAHPS data and e-mail narrative
Number of subjects: 309
Study 17548089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 or 2.5 mg/d)
Number of subjects: 3240
Study 17548089 — intervention group
Group type: COMPARATOR
Intervention: CEE-MPA (continuous combined conjugated equine estrogen and medroxyprogesterone acetate)
Number of subjects: 3240
Study 16342344 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler myocardial imaging in patients with uncontrolled hypertension
Number of subjects: 33
Study 16342344 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler myocardial imaging in patients with controlled hypertension
Number of subjects: 33
Study 16342344 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Doppler parameters in patients with uncontrolled hypertension
Number of subjects: 33
Study 16342344 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Doppler parameters in patients with controlled hypertension
Number of subjects: 33
Study 16342344 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 33
Study 15259390 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT)
Number of subjects: 30
Study 15259390 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock-related cognition tests
Number of subjects: 30
Study 15259390 — intervention group
Group type: COMPARATOR
Intervention: Clock face copying and time representation selection
Number of subjects: 30
Study 10505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus (HCV) antibody
Number of subjects: 2166
Study 10505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 2166
Study 10505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2166
Study 10505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 2166
Study 10505303 — intervention group
Group type: EXPERIMENTAL
Intervention: No obvious aetiology
Number of subjects: 2166
Study 10505303 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B core antibody (HBcAb)
Number of subjects: 2166
Study 8949812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TOE) with automated endocardium detection
Number of subjects: 15
Study 8949812 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MD (AL) derived stroke volume
Number of subjects: 15
Study 2022522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioactive chromic phosphate
Number of subjects: 69
Study 7039282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide, 100 mg twice daily
Number of subjects: 10
Study 7039282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7039282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 10
Study 29660951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation with effortful swallowing
Number of subjects: 18
Study 29660951 — intervention group
Group type: COMPARATOR
Intervention: Sham neuromuscular electrical stimulation with effortful swallowing
Number of subjects: 18
Study 27043946 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous application of local anaesthetic through subfascial catheter
Number of subjects: 52
Study 27043946 — intervention group
Group type: COMPARATOR
Intervention: Continuous application of local anaesthetic through subcutaneous catheter
Number of subjects: 52
Study 25780881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) 100 mg/kg infusion 6 hours before donor operation and subsequent infusion of 100 mg/kg every 6 hours until organ removal
Number of subjects: 40
Study 25780881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA)
Number of subjects: 40
Study 23851059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive cardiac resynchronization therapy (aCRT) with synchronized left ventricular pacing (sLVP)
Number of subjects: 478
Study 23851059 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography-optimized biventricular pacing (BVP)
Number of subjects: 478
Study 20855072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 201
Study 20855072 — intervention group
Group type: COMPARATOR
Intervention: Niacin 1500 mg
Number of subjects: 201
Study 18727647 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug and behavioural therapy for acute headache treatment
Number of subjects: 0
Study 18727647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18727647 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive procedures (injections)
Number of subjects: 0
Study 18727647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral drugs
Number of subjects: 0
Study 16834790 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume (60 mL of anaesthetic solution)
Number of subjects: 60
Study 16834790 — intervention group
Group type: COMPARATOR
Intervention: Low volume (30 mL of anaesthetic solution)
Number of subjects: 60
Study 15568952 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld polarized light camera (USB camera)
Number of subjects: 0
Study 15568952 — intervention group
Group type: COMPARATOR
Intervention: 16-bit electronically cooled camera
Number of subjects: 0
Study 10743462 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine 1:200,000
Number of subjects: 40
Study 10743462 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 40
Study 9199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline (300 mg)
Number of subjects: 16
Study 9199943 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 16
Study 1287196 — intervention group
Group type: EXPERIMENTAL
Intervention: Two prototypical ethanol-water flux-enhanced transdermal therapeutic systems
Number of subjects: 6
Study 1287196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype B
Number of subjects: 6
Study 1287196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype A
Number of subjects: 6
Study 1287196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prototypes
Number of subjects: 6
Study 1287196 — intervention group
Group type: COMPARATOR
Intervention: Transderm-Nitro 10
Number of subjects: 6
Study 4005127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oros system with initial release rate of 14 mg/h
Number of subjects: 6
Study 4005127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oros system with initial release rate of 19 mg/h
Number of subjects: 6
Study 3589362 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestagen therapy (lynestrenol)
Number of subjects: 160
Study 3589362 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapy (Mastodynon)
Number of subjects: 160
Study 3589362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 29401266 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-SAV
Number of subjects: 394
Study 29401266 — intervention group
Group type: COMPARATOR
Intervention: Mosaic
Number of subjects: 394
Study 26962903 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (320 mg and 1600 mg, respectively, twice daily for 7 days)
Number of subjects: 1247
Study 26962903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study 26962903 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 1247
Study 25071367 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA/AEA emollient
Number of subjects: 60
Study 25071367 — intervention group
Group type: COMPARATOR
Intervention: Traditional emollient
Number of subjects: 60
Study 21982391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row rotator cuff repair
Number of subjects: 53
Study 21982391 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row rotator cuff repair
Number of subjects: 53
Study 21982391 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 53
Study 20858114 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg triamcinolone acetonide monotherapy (n=17)
Number of subjects: 52
Study 20858114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab monotherapy (n=14)
Number of subjects: 52
Study 20858114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 mg triamcinolone acetonide and 1.25 mg bevacizumab (n=21)
Number of subjects: 52
Study 18178372 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test B (TMT B)
Number of subjects: 526
Study 18178372 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic classification accuracy
Number of subjects: 526
Study 18178372 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test A (TMT A)
Number of subjects: 526
Study 16139963 — intervention group
Group type: EXPERIMENTAL
Intervention: Project EX smoking cessation clinic
Number of subjects: 18
Study 16139963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 15931282 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg/day elemental iron)
Number of subjects: 0
Study 15931282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10683053 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical pathway intervention (n = 9 hospitals)
Number of subjects: 1743
Study 10683053 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (n = 10 hospitals)
Number of subjects: 1743
Study 9100599 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg
Number of subjects: 20
Study 9100599 — intervention group
Group type: COMPARATOR
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 20
Study 8096880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 0.4 mg
Number of subjects: 14
Study 8096880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 0.2 mg
Number of subjects: 14
Study 8096880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2879736 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (160 mg)
Number of subjects: 24
Study 2879736 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (4 mg)
Number of subjects: 24
Study 2879736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31101018 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 times per week hemodialysis
Number of subjects: 44
Study 31101018 — intervention group
Group type: COMPARATOR
Intervention: 3 times per week hemodialysis
Number of subjects: 44
Study 29498049 — intervention group
Group type: EXPERIMENTAL
Intervention: Amustaline-treated RBCs
Number of subjects: 51
Study 29498049 — intervention group
Group type: COMPARATOR
Intervention: Conventional RBCs (control)
Number of subjects: 51
Study 26656773 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR + N (narrow cuff, 5 cm)
Number of subjects: 11
Study 26656773 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR + W (wide cuff, 10 cm)
Number of subjects: 11
Study 25351118 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tumor biopsies in NBI mode (Group B)
Number of subjects: 113
Study 25351118 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal tumor biopsies in white light mode (Group A)
Number of subjects: 113
Study 22998983 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Stimulation Therapy (iCST) sessions delivered by a carer for 30 minutes, 3 times a week over 25 weeks
Number of subjects: 306
Study 22998983 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 306
Study 20543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded dynamic squats with WBV (45 Hz)
Number of subjects: 13
Study 20543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded dynamic squats without WBV (30% of body mass)
Number of subjects: 13
Study 20543737 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded dynamic squats with WBV (45 Hz)
Number of subjects: 13
Study 20543737 — intervention group
Group type: COMPARATOR
Intervention: Unloaded dynamic squats without WBV
Number of subjects: 13
Study 18212032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization
Number of subjects: 92
Study 18212032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization - TENS
Number of subjects: 92
Study 18212032 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 92
Study 18212032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 16156943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 0
Study 11810078 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-cm² patch (Ortho Evra)
Number of subjects: 610
Study 11810078 — intervention group
Group type: COMPARATOR
Intervention: Ortho-Cyclen
Number of subjects: 610
Study 11810078 — intervention group
Group type: EXPERIMENTAL
Intervention: All patch regimens
Number of subjects: 610
Study 10935771 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 37
Study 10935771 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctr)
Number of subjects: 37
Study 8959872 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 122
Study 8959872 — intervention group
Group type: COMPARATOR
Intervention: Conversion from CsA to azathioprine
Number of subjects: 122
Study 1283730 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I (40 micrograms/kg by single subcutaneous dose)
Number of subjects: 30
Study 1283730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 4025678 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified contract-relax (CR) method, trained three times a week for 30 days (14 training sessions)
Number of subjects: 47
Study 4025678 — intervention group
Group type: COMPARATOR
Intervention: Traditional ballistic stretch (BS) method, trained during the same time for 30 days
Number of subjects: 47
Study 4025678 — intervention group
Group type: EXPERIMENTAL
Intervention: Training frequency of once a week for 30 days after initial training
Number of subjects: 47
Study 4025678 — intervention group
Group type: EXPERIMENTAL
Intervention: Training frequency of three times a week for 30 days after initial training
Number of subjects: 47
Study 4025678 — intervention group
Group type: EXPERIMENTAL
Intervention: Training frequency of five times a week for 30 days after initial training
Number of subjects: 47
Study 30043192 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based sensory interventions plus standard therapy
Number of subjects: 40
Study 30043192 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (speech therapy and applied behavior analysis)
Number of subjects: 40
Study 28009070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 20
Study 28009070 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 20
Study 28009070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22964975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day) for 12 weeks
Number of subjects: 0
Study 22964975 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 22097160 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug injection (ropivacaine, morphine, ketorolac, and epinephrine)
Number of subjects: 30
Study 22097160 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 22097160 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug injection
Number of subjects: 30
Study 19213683 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation (including $100 for program completion, $250 for cessation within 6 months, and $400 for abstinence for an additional 6 months)
Number of subjects: 878
Study 19213683 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation
Number of subjects: 878
Study 16967054 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nurse-delivered intervention
Number of subjects: 105
Study 16967054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 12720237 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI)
Number of subjects: 149
Study 12720237 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI)
Number of subjects: 149
Study 10966889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (providing 2.0 g EPA/d and 1.4 g DHA/d)
Number of subjects: 15
Study 10966889 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (providing 12.3 g oleate/d)
Number of subjects: 15
Study 10966889 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (providing 10.5 g linoleate/d)
Number of subjects: 15
Study 9201636 — intervention group
Group type: COMPARATOR
Intervention: Static stretch (30 seconds, twice daily)
Number of subjects: 40
Study 9201636 — intervention group
Group type: COMPARATOR
Intervention: Active stretch (30 repetitions of active knee extension while sitting in a neural slump position, twice daily)
Number of subjects: 40
Study 9201636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 8431573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 8431573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2887723 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-work services for six months
Number of subjects: 345
Study 2887723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social-work services)
Number of subjects: 345
Study 31149747 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity assessment using the Barthel Index, Lawton and Brody Scale, Evaluation Form of Dependence in Self-care, Self-care of Home Dwelling Elderly (self-care subscale profiles)
Number of subjects: 313
Study 31149747 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of functional capacity and self-care profile
Number of subjects: 313
Study 30019970 — intervention group
Group type: EXPERIMENTAL
Intervention: 755-nm picosecond pulsed alexandrite laser treatments (4 treatments, spaced 3 weeks apart)
Number of subjects: 20
Study 30019970 — intervention group
Group type: COMPARATOR
Intervention: 1927-nm fractionated thulium laser treatments (2 treatments, spaced 6 weeks apart)
Number of subjects: 20
Study 27802253 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (outpatient, intensive back school)
Number of subjects: 58
Study 27802253 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 58
Study 26678633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesion abciximab
Number of subjects: 128
Study 26678633 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary abciximab
Number of subjects: 128
Study 26678633 — intervention group
Group type: COMPARATOR
Intervention: Aspiration thrombectomy
Number of subjects: 128
Study 26678633 — intervention group
Group type: EXPERIMENTAL
Intervention: No aspiration thrombectomy
Number of subjects: 128
Study 24283160 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavones supplementation (60.8 mg red clover isoflavones plus 19.2 mg soy isoflavones)
Number of subjects: 150
Study 24283160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21596867 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of autologous blood
Number of subjects: 121
Study 21596867 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of autologous blood
Number of subjects: 121
Study 21596867 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of autologous blood
Number of subjects: 121
Study 21596867 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study 18444850 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (1 g, intravenously once daily for 3 consecutive days)
Number of subjects: 200
Study 18444850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated group
Number of subjects: 1039
Study 17547070 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated group
Number of subjects: 1039